PAB.AX
Patrys Limited
A$0.03
+0.00 +3.33% today
Price History
Not enough data
Key Stats
Market Cap
10.86M
Avg Volume
299,899
EPS
-A$0.02
52W High
A$0.05
52W Low
A$0.03
Div. Yield
0.0%
Valuation
P/B Ratio
2.07
P/S Ratio
1209.17
EV/EBITDA
-4.13
EV/Revenue
1570.04
Margins
Gross Margin 100.0%
Operating Margin (5896.4%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
(93.2%)
Return on Equity
(68.2%)
Return on Assets
(35.8%)
Liquidity & Leverage
Current Ratio
3.84
Quick Ratio
3.77
Total Cash
3.36M
Total Debt
0
About
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
patrys.com